Brocair Partners

Brocair Partners is a financial advisory firm founded in 2004 that specializes in mergers and acquisitions, corporate finance, and strategic advisory services for businesses serving the healthcare, wellness, and pharmaceutical industries. The firm operates globally from its New York headquarters, working with clients ranging from privately-held companies to publicly-traded entities across multiple continents.

The firm's capabilities span both sell-side and buy-side M&A advisory, with demonstrated experience managing complex cross-border transactions. Brocair has handled deals involving pharmaceutical API manufacturers, life science technology companies, dental products manufacturers, and biopharmaceutical equipment providers. The team manages controlled auction processes, coordinates due diligence, and negotiates transaction terms while maintaining confidentiality throughout the deal lifecycle.

Notable transactions include the €37 million sale of TangenX Technology Corporation to Repligen, the sale of Synthetech to W.R. Grace & Co. at a 158% premium over trading price, and the sale of Swedish dental products company Biomain AB to Heraeus Kulzer for over SEK 200 million. The firm also produces industry perspectives on healthcare sectors, including healthcare insurance services.

Choose Brocair Partners when seeking specialized M&A advisory for healthcare and pharmaceutical transactions that require deep sector knowledge and global reach. The firm excels in managing competitive auction processes for companies in specialized niches where understanding technical aspects and identifying non-obvious strategic buyers creates value.

Expect a hands-on advisory approach with senior partner involvement throughout negotiations and transaction management. The firm's experience coordinating multiple stakeholders, minority shareholders, and complex approval processes makes them particularly effective for sophisticated cross-border deals requiring careful management of timing and confidentiality.

Brocair Partners focuses exclusively on healthcare, wellness, and pharmaceutical industries, with particular depth in pharmaceutical active ingredients (APIs), life science technologies, biopharmaceutical manufacturing equipment, and dental products. The firm demonstrates understanding of complex healthcare supply chains, regulatory environments, and the technical aspects of healthcare manufacturing businesses.

Their industry perspective work includes analysis of healthcare insurance services, pharmacy benefit management, and the impact of healthcare reform on business models, indicating breadth of knowledge across the healthcare ecosystem beyond their core M&A practice areas.

The ideal client is a mid-market healthcare or pharmaceutical company with $10-100 million in revenue operating in specialized sectors such as pharmaceutical ingredients, life science technologies, medical devices, or dental products. The company may be privately-held or publicly-traded, potentially with complex ownership structures including minority shareholders, and requires sophisticated M&A advisory to maximize value through a controlled auction process.